Connect Biopharma Holdings Ltd (CNTB) shareholders
Close on Nov 17, 2026Market cap $36.45MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Panacea Innovation Limited Joint filing with Panacea Venture Healthcare Fund II, L.P. (21.20%), Panacea Venture Healthcare Fund II GP Company, Ltd. (21.20%) and 1 more | 13,160,000 | 21.20% | 13D (active) amendment | Mar 31, 2026 |
| Wubin Pan Joint filing with BioFortune Inc (9.50%) | 6,026,813 | 9.60% | 13G (passive) | Apr 14, 2026 |
| Zheng Wei | 5,015,960 | 9.00% | 13G (passive) amendment | Dec 31, 2025 |
| Ikarian Capital, LLC Joint filing with Neil Shahrestani (6.90%) | 4,338,534 | 6.90% | 13G (passive) amendment | Jun 30, 2026 |
| Braden M Leonard Joint filing with BML Investment Partners, L.P. (6.10%) | 4,264,400 | 6.77% | 13G (passive) | Sep 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CNTB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ikarian Capital, LLC | 4,538,534 | 7.21% | $10.80M | −849,952 | 1.16% |
| 683 Capital Management, LLC | 1,285,000 | 2.04% | $3.06M | +385,000 | 0.15% |
| Boothbay Fund Management, LLC | 973,732 | 1.55% | $2.32M | −260,850 | 0.03% |
| BlackRock, Inc. | 871,653 | 1.38% | $2.07M | New | 0.00% |
| Perceptive Advisors LLC | 792,696 | 1.26% | $1.89M | – | 0.03% |
| ADAR1 Capital Management, LLC | 700,000 | 1.11% | $1.67M | −42,400 | 0.08% |
| BML Capital Management, LLC | 573,287 | 0.91% | $1.36M | +164,400 | 0.78% |
| Silverarc Capital Management, LLC | 545,000 | 0.87% | $1.30M | New | 0.13% |
| Richmond Brothers, Inc. | 535,612 | 0.85% | $1.27M | +59,028 | 0.66% |
| Knott David M Jr | 444,862 | 0.71% | $1.06M | +57,027 | 0.56% |
| Stonepine Capital Management, LLC | 364,254 | 0.58% | $866.93K | +54,254 | 0.49% |
| Marshall Wace, Llp | 335,642 | 0.53% | $798.83K | +269,629 | 0.00% |
| Geode Capital Management, LLC | 257,454 | 0.41% | $612.74K | +225,325 | 0.00% |
| Two Sigma Investments, LP | 199,381 | 0.32% | $474.53K | +151,916 | 0.00% |
| Diadema Partners LP | 196,985 | 0.31% | $468.82K | −3,705 | 0.06% |
| Burkehill Global Management, LP | 150,000 | 0.24% | $357.00K | – | 0.01% |
| Vanguard Portfolio Management LLC | 102,755 | 0.16% | $244.56K | New | 0.00% |
| Susquehanna International Group, Llp | 102,148 | 0.16% | $243.11K | −176,660 | 0.00% |
| Renaissance Technologies LLC | 87,300 | 0.14% | $207.77K | −33,400 | 0.00% |
| Northern Trust Corp | 82,862 | 0.13% | $197.21K | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 56 | 14M | 22.1% | 25 / 15 | 9 / 10 | 3M | 2M |
| Q1 2026 | 41 | 13M | 20.2% | 15 / 9 | 7 / 3 | 5M | 0M |
| Q4 2025 | 29 | 8M | 13.4% | 15 / 5 | 5 / 2 | 8M | 1M |
| Q3 2025 | 16 | 2M | 2.6% | 5 / 4 | 3 / 6 | 0M | 1M |
| Q2 2025 | 17 | 2M | 3.9% | 6 / 2 | 3 / 1 | 0M | 1M |
| Q1 2025 | 13 | 3M | 4.5% | 1 / 1 | 4 / 2 | 0M | 0M |
| Q4 2024 | 14 | 3M | 5.1% | 5 / 2 | 2 / 2 | 0M | 0M |
| Q3 2024 | 11 | 3M | 4.7% | 2 / 3 | 1 / 2 | 0M | 0M |
| Q2 2024 | 12 | 3M | 4.7% | 2 / 1 | 4 / 2 | 0M | 1M |
| Q1 2024 | 12 | 4M | 6.3% | 2 / 1 | 4 / 5 | 0M | 3M |
| Q4 2023 | 15 | 7M | 11.3% | 4 / 3 | 6 / 3 | 2M | 5M |
| Q3 2023 | 14 | 10M | 16.0% | 1 / 3 | 2 / 3 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Barry D. Quart | Chief Executive Officer, Director | 224,034 | 0.36% | Mar 16, 2026 |
| Lisa Peraza | Senior Vice President, Finance | 45,189 | 0.07% | Mar 16, 2026 |
| David Leslie Szekeres | President | 215,739 | 0.34% | Mar 16, 2026 |
| Jean I. Liu | Director | 20,763 | 0.03% | Oct 1, 2026 |
| Kleanthis Gabriel Xanthopoulos | Director | 91,554 | 0.15% | Oct 1, 2026 |
| James Huang | Director | 13,310,000 | 21.14% | Jun 2, 2026 |
| James A. Schoeneck | Director | – | – | Mar 16, 2026 |
| Karen J. Wilson | Director | 10,000 | 0.02% | Mar 16, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Kleanthis Gabriel Xanthopoulos Director | Sep 30, 2026 | Award | +5,000 | – | – | 91,554 |
| Jean I. Liu Director | Sep 30, 2026 | Award | +8,984 | – | – | 20,763 |
| Kleanthis Gabriel Xanthopoulos Director | Jun 30, 2026 | Award | +3,738 | – | – | 86,554 |
| Jean I. Liu Director | Jun 30, 2026 | Award | +6,718 | – | – | 11,779 |
| James Huang Director | May 29, 2026 | Buy | +150,000 | $2.48 | $372.00K | 13,310,000 |
| Kleanthis Gabriel Xanthopoulos Director | Mar 31, 2026 | Award | +2,816 | – | – | 82,816 |
| Jean I. Liu Director | Mar 31, 2026 | Award | +5,061 | – | – | 5,061 |
| James Huang Director | Mar 31, 2026 | Buy | +1,160,000 | $3.45 | $4.00M | 13,160,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Connect Biopharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 510,315 shares on Oct 1, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Panacea Innovation Limited 10% Owner | Nov 24, 2025 | 2,000,000 | $6.00M | Nov 24, 2025 | The Ordinary Shares were purchased in multiple open market transactions from 2022 through September 2025. |
| Wei Zheng 10% Stockholder | Nov 21, 2025 | 650,000 | $2.07M | Nov 21, 2025 | Compensation- Stock Award |
| BioFortune Inc 10% Stockholder | Nov 18, 2025 | 500,000 | $1.25M | Nov 18, 2025 | Acquired under Employee Incentive Plan as employee of the Securities Issuer |
| Wei Zheng 10% Stockholder | Oct 1, 2025 | 200,000 | $305.94K | Oct 1, 2025 | Compensation- Stock Award |
| Wei Zheng 10% Stockholder | Jun 11, 2025 | 39,775 | $32.22K | Jun 11, 2025 | Compensation-Stock Award |
| RA Capital Healthcare Fund LP 10% Stockholder | Dec 18, 2023 | 1,765,788 | $1.67M | Dec 18, 2023 | IPO Investment |
| RA Capital Nexus Fund, L.P. 10% Stockholder | Dec 18, 2023 | 295,650 | $279.03K | Dec 18, 2023 | Open Market Purchase |
| RA Capital Nexus Fund, L.P. 10% Stockholder | Dec 12, 2023 | 36,959 | $33.26K | Dec 12, 2023 | Open Market Purchase |
| RA Capital Healthcare Fund LP 10% Stockholder | Dec 12, 2023 | 220,738 | $198.66K | Dec 12, 2023 | Open Market Purchase |
| RA Capital Nexus Fund, L.P. 10% Stockholder | Nov 27, 2023 | 151,778 | $195.79K | Nov 27, 2023 | IPO Investment |
| RA Capital Healthcare Fund LP 10% Stockholder | Nov 27, 2023 | 906,504 | $1.17M | Nov 27, 2023 | Open market purchase |
| RA Capital Healthcare Fund LP 10% Stockholder | Nov 21, 2023 | 471,732 | $971.77K | Nov 21, 2023 | IPO Investment |
| RA Capital Nexus Fund, L.P. 10% Stockholder | Nov 21, 2023 | 78,983 | $162.70K | Nov 21, 2023 | IPO Purchase |
See a number that looks wrong?